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Abstract
Introduction: Articular tissues are capable of producing a range of eicosanoid mediators, each of which has
individual biological effects and may be affected by anti-inflammatory treatment. We set out to develop and
evaluate a high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) approach for the
simultaneous analysis of multiple eicosanoid lipid mediators in equine synovial fluid (SF), and to illustrate its use for
investigation of the in vivo effects of non-steroidal anti-inflammatory drug (NSAID) treatment.
Methods: Synovial fluid samples were obtained from normal joints of 6 adult horses at baseline (0 hr) and at 8, 24
and 168 hours after experimental induction of transient acute synovitis, with horses treated once daily with oral
NSAID (meloxicam, 0.6 mg/kg) or placebo. Following solid-phase extraction, SF lipid mediator quantitation was
based on liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) analysis, and
results were compared between disease states using linear discriminant analysis (LDA) and analysis of variance
(ANOVA) with multiple comparisons corrections.
Results: Of a total of 23 mediators targeted, 14 could be reliably identified and quantified in SF samples based on
detection of characteristic fragment ions at retention times similar to those of commercial standards. LDA analysis
of baseline, 8, 24 and 168 hour synovial fluid samples revealed a separation of these groups into discrete clusters,
reflecting dynamic changes in eicosanoid release over the course of synovitis. Prostaglandin (PG) E2 was
significantly lower in NSAID vs. placebo treated samples at all time points; PGE1, 11-hydroxyeicosatetraenoic acid
(11-HETE) and 13,14-dihydro-15keto PGF2a were reduced at 8 and 24 hours by NSAID treatment; while 15-HETE, 6-
keto PGF1a,P G F 2a, 13,14-dihydro-15keto PGE2 and thromboxane B2 (TXB2) were reduced at the 8 hour time point
only. An interesting pattern was seen for Leukotriene B4 (LTB4), NSAID treatment causing an initial increase at 8
hours, but a significant reduction by 168 hours.
Conclusions: The described method allows a comprehensive analysis of synovial fluid eicosanoid profiles.
Eicosanoid release in inflamed joints as well as differences between NSAID treated and placebo treated individuals
are not limited to PGE2 or to the early inflammatory phase.
Introduction
Lipid mediators of inflammation play an important role
in the local inflammatory response associated with
inflammatory arthritides as well as orthopedic arthropa-
thies [1]. Of these mediators, the E-series prostaglandins
(most notably PGE2) are most noted in arthritis research
for their pro-inflammatory and pro-nociceptive actions
in synovial joints [2,3].
However, COX and LOX enzyme activity within the
arachidonic acid cascade generates a range of eicosanoid
mediators that have widely varying biological actions,
including anti-inflammatory and pro-resolving effects
[4,5]. In recent years, more light has been shed on the
specific actions of individual eicosanoids in arthritis, and
several of these (including PGE2) have emerged as
janus-faced mediators with pro-inflammatory or anti-
inflammatory effects depending effects, depending on
concentration and receptor subtype engagement [6,7].
Reduction of PGE2 production is the classical mode of
action of anti-inflammatory agents like non-steroidal
anti-inflammatory drugs (NSAIDs) that are commonly
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numerous studies have demonstrated a lower PGE2 con-
centration in synovial fluid (SF) following NSAID treat-
ment [8-10]. However, by inhibition of COX activity,
these drugs are likely not only to affect PGE2 production
but also to interfere with the production of mediators
with differential effects that are generated by the same
enzymatic pathways. Indeed, in an early study, NSAID
(naproxen) treatment tended to reduce not only PGE2
but also TXB2 and 6-keto PGF1a concentration in the
SF of human patients with rheumatoid arthritis [8].
The investigation of the potential involvement of indi-
vidual eicosanoids in disease states relies on sensitive
and specific assays to measure these products in biologi-
cal fluids. While antibody-based assays for individual
eicosanoids are commonly employed, these suffer from
cross-reactivity issues and may produce misleading
results in complex biological samples [11]. Moreover,
they can be used for analysis of only one metabolite at a
time, restricting the amount of biological information
obtained as SF sample volume tends to be a limiting
factor.
In this report, we describe the application of recently
developed high-performance liquid chromatography-tan-
dem mass spectrometry (HPLC-MS/MS) mediator lipi-
domics techniques to the study of eicosanoid release in
equine synovial joints. To evaluate the relative abun-
dance of these lipid mediator species in normal and
inflamed joints and investigate the effects of COX inhi-
bition on eicosanoid profiles, we performed a longitudi-
nal study of SF lipid mediator composition in healthy
horses over the course of experimentally induced transi-
ent synovitis with and without oral NSAID treatment.
Materials and methods
5(S)-hydroxyeicosatetraenoic acid (HETE), 8(S)-HETE,
11(S)-HETE, 12(S)-HETE, and 15(S)-HETE; leukotriene
D4 (LTD4), LTE4;L T B 4; 5(S)6(R)15(S)-lipoxin A4
(LXA4); prostaglandin E1 (PGE1), 6-keto prostaglandin
F1a (6-keto PGF1a), prostaglandin D2 (PGD2), prosta-
glandin E2 (PGE2), prostaglandin F2a (PGF2a), 11b-
prostaglandin F2a (11b-PGF2a), prostaglandin F2b
(PGF2b), prostaglandin J2 (PGJ2), 15-deoxy-Δ12,14-pros-
taglandin J2 (15-deoxy-Δ12,14-PGJ2), thromboxane B2
(TXB2), 13,14-dihydro-15-keto PGF2a, 13,14-dihydro-
15-keto PGE2, 13,14-dihydro-15-keto PGD2, and 16,16-
dimethyl PGF2a were purchased from Cayman Chemi-
cal Company (Ann Arbor, MI, USA). HPLC-grade sol-
vents (acetonitrile and methanol) were from Biosolve
(Valkenswaard, The Netherlands), and glacial acetic acid
and all other chemicals used for sample extraction and
preparation were from Sigma-Aldrich (St. Louis, MO,
USA). Solid-phase extraction columns (LiChrolut RP-18;
100-mg column bed) were purchased from Merck
(Darmstadt, Germany).
Preparation of standards and calibration lines
Stock standard solutions were prepared in ethanol (100
ng/μL )a n ds t o r e di na m b e rv i a l sa t- 8 0 ° Cu n d e rN 2.
Calibration lines were prepared by diluting the appropri-
ate stock solutions to final concentrations of 100, 50, 25,
1 0 ,5 ,2 ,a n d1p g / μL. The internal standard (IS) (16,16-
dimethyl-PGF2a) was prepared in ethanol (2 ng/μL) and
was added to all composite standards at a final concen-
tration of 100 pg/μL. Chromatograms for standards
were used to establish characteristic retention times
(RTs) of each compound, while the calibration lines
were used to verify that the MS signal was linear for all
analytes over this range. The peak-area ratios of each
analyte to IS (16,16-dimethyl-PGF2a) were calculated
and plotted against the concentration of the calibration
standards. Calibration lines were calculated by the least
squares linear regression method.
Sample collection and storage
SF samples were obtained from a previously reported
cross-over study of NSAID versus placebo treatment in
an equine lipopolysaccharide (LPS)-induced transient
synovitis model [9]. All experimental procedures were
preapproved by the Utrecht University institutional
Ethics Committee on Animal Experimentation. In short,
six healthy adult warmblood horses were subjected to
two episodes of experimental synovitis, once in the right
and once in the left middle carpal joint, with a 2-week
washout period in between. During each experimental
p e r i o d ,h o r s e sw e r er a n d o m l ya s s i g n e dt or e c e i v eo r a l
NSAID treatment (meloxicam, 0.6 mg/kg; Boehringer
Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Ger-
many) or placebo treatment (the same oral suspension
minus the active substance) starting at t = 2 hours after
LPS and at 24-hour intervals thereafter (26, 50, 74, 98,
122, and 146 hours after LPS) for a total of seven treat-
ments. In each experimental period, SF samples were
a s p i r a t e da tb a s e l i n e( t=0 ,j u s tp r i o rt oL P Si n j e c t i o n )
and 8, 24, and 168 hours after LPS. Samples were cen-
trifuged at 10,000g immediately after collection, and
supernatants were aliquotted and transferred to -80°C
within 30 minutes; samples were stored at -80°C await-
ing extraction.
Sample preparation
SF aliquots (300 μL) were thawed on ice. IS (20 μLo fa
200 pg/μL solution of 16,16-dimethyl PGF2a) was added
to each sample. Samples were diluted with 1.5 mL of
15% (vol/vol) methanol in 0.1% (vol/vol) formic acid and
0.002% (vol/vol) butylated hydroxytoluene (BHT) (an
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centrifuged at 10,000g for 15 minutes at 4°C to remove
any precipitated proteins. The resulting clear superna-
tants were decanted and kept on ice. Pellets were
washed with a further 1.2 mL of 15% (vol/vol) methanol
in 0.1% (vol/vol) formic acid and 0.002% (vol/vol) BHT
and again were centrifuged for 10 minutes at 10,000g
and 4°C, after which this supernatant was added to that
previously collected, making a total sample volume of 3
mL.
This sample was applied to RP-18 solid-phase extrac-
tion columns (100 mg) that had been preconditioned
with 1 mL of acetone followed by 1 mL of 15% (vol/vol)
methanol in 0.1% (vol/vol) formic acid. The columns
were then washed with 1 mL of 15% (vol/vol) methanol
in 0.1% (vol/vol) formic acid, 2 × 1 mL of water, and 1
mL of hexane. Lipid mediators were eluted into amber
vials containing silanized glass inserts using 3 × 250 μL
volumes of ethylacetate. The eluate was evaporated
under nitrogen; the residue was dissolved in 40 μLo f
e t h a n o l ,f l u s h e dw i t hn i t r o g e n ,a n ds t o r e da t- 8 0 ° C
awaiting HPLC-MS/MS analysis.
High-performance liquid chromatography-tandem mass
spectrometry analysis
HPLC-MS/MS analysis was performed on a PerkinElmer
LC200 HPLC system (PerkinElmer, Waltham, MA,
USA) coupled to an electrospray ionization (ESI) linear
ion trap quadrupole (4000 QTRAP) mass spectrometer
(Applied Biosystems, Nieuwerkerk aan den IJssel, The
Netherlands). The instrument was operated in the nega-
tive ionization mode. For all experiments, the ion source
voltage was -4,500 V and the source temperature was
350°C. Multiple reaction monitoring (MRM) of 26
mass-to-charge (m/z) transitions was used for com-
pound quantification, and declustering potential and
collision energy (using nitrogen as collision gas) were
empirically optimized for each compound (Table 1).
Chromatographic analysis was performed on a C18
column (Luna, 2.5 μm 100 × 3 mm; Phenomenex, Tor-
rance, CA, USA). The injection volume was 10 μL, and
the flow rate 0.2 mL/minute. The column was main-
tained at ambient temperature. The analysis was per-
formed by using a linear gradient obtained by mixing
solvents A (0.02% (vol/vol) glacial acetic acid in water)
and B (0.02% (vol/vol) glacial acetic acid in acetonitrile)
as follows: from 0 to 1 minute: 80% A, from 1 to 17
minutes: 63% A; from 17 to 18 minutes: 52% A; from 18
to 23 minutes: 100% B; and from 24 to 25 minutes: 80%
A.
Data analysis
Automatic peak detection and integration were per-
formed by using the XCMS software package [12]. Data
were processed by using XCMS version 1.22.1 running
under R version 2.11.0. The signal-to-noise ratio for
peak detection was set to 10. Zero values, in samples
with missing peaks, were prevented by forced integra-
tion at the calculated expected RT of the peak. Linear
discriminant analysis (LDA) was performed by using
MarkerView software (MarkerView 1.1.0.7; Applied Bio-
systems, Foster City, CA, USA) and visualized graphi-
cally using GraphPad (GraphPad Prism version 5.2 for
Windows; GraphPad Software, San Diego, CA, USA).
Significance was tested by using analysis of variance and
t tests with Welch’s correction for unequal variances.
Since relatively large numbers of peaks were tested
simultaneously, small P values occurred by chance and
false-positives were expected; these were corrected for
by using the R package MULTTEST [13,14].
Results
Extraction efficiency
Analyte recovery was estimated by comparing the peak
area of the IS added to each SF sample prior to extrac-
tion, and the peak-area value was obtained in the pure
(that is, unextracted) IS solution. In both conditions, a
total of 1,000 pg of 16,16-dimethyl PGF2a was brought
on-column assuming 100% extraction efficiency. Mean
(± standard deviation) recovery of IS in SF samples (n =
48) was 69.5% ± 10.8% (range of 48.7% to 90.4%).
Linearity
Calibration curves of standards showed excellent linear-
ity over a concentration range of 1 to 100 pg/μL (corre-
sponding to 10 to 1,000 pg on-column), and correlation
coefficients were greater than 0.99 for all analytes except
for 8-HETE (r =0 . 9 8 8 )a n d5 - H E T E( r =0 . 9 6 9 ) .S e e
Figure S1 of Additional file 1.
Eicosanoid identification and quantitation
Reconstructed chromatograms of SF samples showed
adequate peak resolution (Figure 1), and inclusion of
more than one MRM transition for an analyte proved to
be a useful adjunct to chromatographic resolution for
analyte identification (Figure 2). Peaks were integrated
and RTs were compared with those of commercially
available standards of the compound of interest. Only
peaks with the correct combination of m/z transition
a n dR Tw e r ec o n s i d e r e dt ob ep o s i t i v e l yi d e n t i f i e da s
the analyte of interest and were subsequently quanti-
tated with reference to the standard curve of the parti-
cular analyte (Figure S1 of Additional file 1).
Unidentified peaks (that is, m/z transitions detected at
non-characteristic RTs for the analyte of interest) were
evaluated for alternative processes that might generate
such peaks, such as (source) fragmentation of closely
related mediators eluting at that RT. All monitored m/z
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cebo-treated samples at each time point (Figure 3); this
statistical method analyzes complex data by graphically
presenting the degree of (dis)similarity between samples
belonging to the same or to different groups on the
basis of variables measured in each sample (in this case,
m/z transitions). The corresponding loading plot (Figure
4) shows which fragments contributed most to the
observed difference (that is, spatial separation) between
samples belonging to different groups; those mediators
that are furthest from the intercept of both axes (the 0
distance point) contribute most to this distinction (that
is, PGE2,L T B 4, 5-HETE, 11-HETE, 6-keto PGF1a,
PGF2a, 13,14-dihydro-15-keto PGF2a, and TXB2). Con-
centration profiles of individual eicosanoids in SF over
the course of synovitis with or without NSAID treat-
ment are shown in Figures 5 (prostanoids) and 6
(HETEs and LTB4).
Discussion
In this report, we describe the application of mediator
lipidomics techniques to the study of SF eicosanoid
profiles in normal and inflamed equine joints. Further-
more, we illustrate the use of the developed LC-ESI-
MS/MS analysis to investigate the effects of NSAID
treatment in acute synovitis.
We identified and quantitated 14 individual eicosa-
noids in SF extracts by using MRM. The MRM transi-
tions used to identify individual compounds in this
s t u d yw e r ec o n f i r m e db yl i t erature sources [15-23];
unfortunately, as previously outlined by Murphy and
colleagues [20], many eicosanoids have very similar or
even identical (isomeric) chemical structures and there-
fore a single m/z transition may not be as specific to
individual compounds as desired. Future experiments
employing information-dependent acquisition in combi-
nation with enhanced product ion detection settings
could be used to enhance analyte identification [24].
Alternatively, the use of more than one m/z transition
per compound (as was done in the present case for
TXB2 and PGE2) could aid in definitive identification.
The recovery of analytes in this study was estimated
by comparing peak areas of the IS in spiked and
extracted SF samples with the corresponding standard
Table 1 Multiple reaction monitoring transitions for liquid chromatography-tandem mass spectrometry assay of
eicosanoids
Compound MRM, m/z Collision energy, eV Declustering potential
PGE1 353 ® 317 -30 -80
6-keto PGF1a 369 ® 163 -35 -100
PGD2 351 ® 271 -25 -40 and -80
PGE2 351 ® 271 -25 -40 and -80
351 ® 175 -30 -80
PGF2a 353 ® 193 -35 -90
11b-PGF2a 353 ® 309 -20 -60
PGF2b 353 ® 309 -25 -40
PGJ2 333 ® 189 -25 -40
333 ® 271 -25 -80
15-deoxy-Δ-12,14 PGJ2 315 ® 271 -20 -90
13,14-dihydro-15-keto PGD2 351 ® 207 -27 -80
13,14-dihydro-15-keto PGE2 351 ® 333 -17 -80
13,14-dihydro-15-keto PGF2a 353 ® 113 -40 -100
TXB2 369 ® 195 -23 -80
369 ® 169 -25 -90
LTB4 335 ® 195 -20 -100
5(S)-HETE 319 ® 115 -20 -40
8(S)-HETE 319 ® 155 -20 -80
11(S)-HETE 319 ® 167 -20 -80
12(S)-HETE 319 ® 179 -20 -80
15(S)-HETE 319 ® 175 -20 -80
LTD4 495 ® 177 -30 -100
LTE4 438 ® 333 -25 -100
LXA4 351 ® 235 -20 -80
16,16-dimethyl PGF2a (IS) 381 ® 319 -35 -100
eV, electron volts; HETE, hydroxyeicosatetraenoic acid; IS, internal standard; LT, leukotriene; LX, lipoxin; MRM, multiple reaction monitoring; m/z, mass/charge; PG,
prostaglandin; TX, thromboxane.
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vides an indication of analyte loss over the extraction
procedure, it does not account for possible differences
in recovery or degradation between individual analytes.
While it is certainly not uncommon to use only one IS
in studies of multiple analytes [15,21,25], it would be
preferable to use stable isotope-labeled standards for
each analyte under investigation or to use one such
labeled standard per class of mediators targeted [24].
However, the 16,16-dimethyl PGF2a we employed does
combine several advantages for use as an IS in the cur-
rent application: It elutes at an RT close to that of many
Figure 1 Representative reconstructed chromatograms of synovial fluid extracts. Total ion count (counts per second, or cps) versus time
in a placebo-treated sample (top panel) at t = 8 hours after lipopolysaccharide and an 8-hour non-steroidal anti-inflammatory drug-treated
sample (bottom panel) from the same subject. Note the difference in scales on the y-axes between top and bottom panels. HETE,
hydroxyeicosatetraenoic acid; IS, internal standard; LT, leukotriene; PG, prostaglandin; TX, thromboxane.
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perature and at -20°C and -80°C (de Grauw, unpub-
lished observations), and it is not normally found in SF
and is not known to have a biological function in syno-
vial joints.
In addition to rapid enzymatic conversion and degra-
dation of lipid mediators in vivo, the reliable analysis of
eicosanoids in body fluids may be hampered by ex vivo
degradation of labile species [24]. This was recently
demonstrated for PGD2, which was shown to be far
more susceptible to chemical decomposition at room
temperature and at -20°C than PGE2 [23]. Hence, rela-
tive quantities of these mediators in extracted samples
may also reflect selective degradation of one over the
other, and absolute levels should be interpreted with
caution; the same might be true for other eicosanoids,
the stability of which has not been exhaustively
addressed. For instance, the current extraction proce-
dure and HPLC solvent system are not optimized for
quantitative detection of cysteinyl LTs [25].
We positively identified 14 eicosanoids in SF extracts
and found that the concentrations of many of these
were significantly elevated in inflamed joints compared
with normal (baseline) values (Figures 5 and 6). As LPS
induces marked influx of leukocytes (predominantly
neutrophils [9]) into the joint space, eicosanoid species
detected may partly reflect release by infiltrating cells
rather than release from articular sources; however,
articular cartilage and, especially, synovial fibroblasts are
apt producers of a great number of these mediators
[17,26,27], and therefore having the means to detect
these will aid in future studies of spontaneous disease.
SF eicosanoid profiles changed dramatically upon
synovitis induction, as illustrated by the LDA plots
showing marked separation between samples taken at
different time points. Release of individual prostanoids,
HETEs, and LTB4 over the course of transient synovitis
did not reveal marked temporal differences between
these classes of mediators, although there was a trend
toward early response of prostanoids versus a somewhat
Figure 2 Extracted ion chromatogram of mass transition 351®271 in an 8-hour synovitis sample. The separate peaks show excellent
chromatographic resolution of geometrical isomers prostaglandin E2 (PGE2) and PGD2. The low-abundant peak at 351®175 (inset) coincides
with the first peak of the main trace, confirming the identity of this analyte as PGE2 rather than PGD2. Note the difference in scales of the left y-
axis (showing ion count for PGE2) and the right y-axis (PGD2). cps, counts per second; m/z, mass/charge.
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and PGE2 as well as PGJ2 (which is an intermediate
breakdown product of PGD2 and which is known to
have anti-inflammatory properties [28,29]) showed a
more prolonged elevation over the first 24 hours of
synovitis than other prostanoids. Although our method
quantitatively detected 15-deoxy-Δ12,14-PGJ2 in stock
standards and in spiked SF, this anti-inflammatory PG
was not detected in SF extracts and hence we cannot
comment on its temporal release pattern. The same was
true for LXA4, another endogenous anti-inflammatory
and pro-resolving mediator [5]. Some of these species
may have escaped detection because of rapid enzymatic
conversion or chemical instability as noted above; thus,
the precise release kinetics of pro- versus anti-inflamma-
tory eicosanoid species in acute synovitis will need to be
addressed in future studies that include even earlier
sampling time points or alternative extraction steps or
both.
The observed differences between NSAID- and pla-
cebo-treated samples clearly demonstrate that the effects
of COX inhibitors on synovial eicosanoid release are not
limited to PGE2 reduction. Concentrations of many
other prostanoids, including PGE1,P G D 2,P G J 2,P G F 2a,
6-keto PGF1a,a n dT X B 2, were also significantly lower
in NSAID- versus placebo-treated SF samples, particu-
larly in the acute phase of synovitis, and this agrees with
and extends previous findings in SF of human subjects
treated with naproxen [8]. The observed reduction in
PGE2 and 6-keto PGF1a (the stable main metabolite of
prostacyclin) with NSAID treatment is likely to contri-
bute to analgesic efficacy [30]. Inhibition of PGE2 and
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Figure 3 Linear discriminant analysis showing discriminant 2 versus 1 of synovial fluid eicosanoid profiles. Samples were taken at four
separate time points (0, 8, 24, and 168 hours) from individuals treated with non-steroidal anti-inflammatory drug (NSAID) (n = 6) or placebo (n =
6) over the course of transient acute synovitis. Linear discriminant analysis finds a linear combination of features (’discriminants’) that characterize
or separate two or more classes of subjects (in this case, samples). Seven classes were predefined: 0 hours (baseline, no treatment administered
yet), 8 hours of placebo, 8 hours of NSAID, 24 hours of placebo, 24 hours of NSAID, 168 hours of placebo, and 168 hours of NSAID. The x- and
y-axes denote discriminant 1 (D1) and discriminant 2 (D2), respectively. D1 has a slightly higher weighing factor than discriminant 2 (D2) as D1
explains 24.9% of the observed variance between classes and D2 22.6%. The distance between groups in this plot denotes the degree of
dissimilarity between samples belonging to each group.
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these two mediators on matrix metalloproteinase
(MMP) production by synovial fibroblasts [28]; however,
as meloxicam itself inhibits synovial MMP activity [9],
this will not have clinical implications. The conse-
quences of TXB2,P G D 2,a n dP G J 2 inhibition are harder
to predict because their roles in arthritis have been less
well studied.
Our results for LTB4 and 5-, 12-, and 15-HETE are
interesting because these mediators are all products of
the LOX pathway but proved to be differentially
affected by NSAID treatment. Both LTB4 and 5-HETE
are downstream products of 5-LOX, 12-HETE is pro-
duced through 12-LOX action, and 15-HETE is pro-
duced by 15-LOX (while both 11- and 15-HETE can
also be produced by COX [31]). As seen in Figure 6,
12-HETE concentration did not change at all over the
course of transient synovitis, whereas the concentra-
tion of 15-HETE was significantly elevated in the acute
phase and reduced by NSAID treatment. Interestingly,
the concentration of LTB4 was significantly higher at 8
hours in SF of NSAID-treated versus placebo-treated
horses, and 5-HETE showed a similar trend. A transi-
ent increase in LTB4 release has also been found in
cultured synovial membrane and cartilage explants
treated with certain COX inhibitors [28,32] and has
been suggested to be due to ‘shunting’ of arachidonic
acid away from COX-mediated PG production toward
LOX-mediated LT production [28]. However, our find-
ings suggest that this is an oversimplification since
such a general shunt would have resulted in elevated
concentrations of all LOX-generated mediators rather
than some of them. Perhaps more likely, different LOX
isoforms or additional enzymes (or both) that are
Figure 4 Loading plot pertaining to linear discriminant analysis of synovial fluid eicosanoid profiles. Samples were taken at four separate
time points (0, 8, 24, and 168 hours) from individuals treated with non-steroidal anti-inflammatory drug (n = 6) or placebo (n = 6) over the
course of transient acute synovitis. The loading plot shows all detected mass transitions, highlighting those that contributed most to the
observed differences (spatial separation) between samples over time and with treatment. Points denoting mass transitions that are furthest away
from the intercept of both axes contributed most to the differences between samples (labeled with mediator name if positively identified or
with mass transition and retention time when the identity could not be confirmed by reference to commercial standards), whereas those close
to the intercept depict mass transitions that were common to most samples. HETE, hydroxyeicosatetraenoic acid; LT, leukotriene; m/z, mass/
charge; PG, prostaglandin; TX, thromboxane.
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Page 8 of 12Figure 5 Concentration of prostanoid species in synovial fluid over the course of lipopolysaccharide-induced synovitis. Horses were
treated with a non-steroidal anti-inflammatory drug (NSAID) (meloxicam, 0.6 mg/kg once a day by mouth; n = 6) or placebo (n = 6) starting at
2 hours after lipopolysaccharide injection for a total of seven treatments. Boxes depict median and interquartile range; whiskers denote
minimum and maximum values. *P < 0.05. PG, prostaglandin; TX, thromboxane.
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Page 9 of 12Figure 6 Synovial fluid hydroxyeicosatetraenoic acid (HETE) (a-d) and leukotriene B4 (LTB4) (e) concentrations during
lipopolysaccharide (LPS)-induced synovitis. Horses were treated with a non-steroidal anti-inflammatory drug (NSAID) (meloxicam, 0.6 mg/kg
once a day by mouth; n = 6) or placebo (n = 6) starting at 2 hours after LPS injection for a total of seven treatments. Individual HETEs respond
differentially to LPS and NSAID treatment. Boxes depict median and interquartile range; whiskers denote minimum and maximum values. *P <
0.05.
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Page 10 of 12located within the arachidonic acid cascade and that
act upon intermediate metabolites (for example, phos-
pholipid hydroperoxide glutathione peroxidase) may be
differentially affected by NSAID treatment. Interest-
ingly, LTB4 elevation was no longer observed at later
time points, and, at 168 hours, meloxicam actually
reduced LTB4 concentration. The biological or clinical
implications of this transient rise in LTB4 upon thera-
peutic COX inhibition remain to be established [28]
and are likely to be complex; while LTB4 plays a cru-
cial role in driving inflammatory arthritis [33], it may
also act to rescue COX-generated mediator production
important to resolution of inflammation [34].
Altogether, this study represents a first attempt at
simultaneous quantification of more than 20 lipid med-
iators in SF samples. Despite the more complex data
analysis and inherent difficulty in identification of multi-
ple closely related analytes in complex biological sam-
ples, the ESI-LC-MS/MS method we employed shows
obvious advantages over enzyme-linked immunosorbent
assay-based techniques that require relatively large
volumes of SF for detection of one selected mediator at
a time, while unaccounted-for analyte loss during sam-
ple extraction and cross-reactivity between analytes may
provide misleading results [15,24]. The current approach
allows high-throughput screening of SF samples by
using an IS for estimation of extraction efficiency and
requires only 300 μLo fS Ft oa n a l y z eam u c hw i d e r
spectrum of eicosanoids, thus enabling the detection of
mediators and treatment effects that otherwise would
have escaped attention.
Conclusions
We report the application of a sensitive HPLC-MS/MS
technique for the simultaneous detection of more than
20 eicosanoids in SF. Extraction efficiency was deemed
adequate, and the method showed good linearity and
sensitivity. The application of this method to SF samples
from horses with experimentally induced synovitis trea-
ted with NSAID or placebo confirmed local release of
many more eicosanoids than PGE2 alone over the
course of transient synovitis and revealed differential
effects of NSAID treatment on several of these media-
tors: PGE2 was significantly lower in NSAID- versus pla-
cebo-treated samples at all time points; PGE1, 11-HETE,
and 13,14-dihydro-15-keto PGF2a were reduced
throughout the acute phase (8 and 24 hours) by NSAID
treatment; whereas 15-HETE, 6-keto PGF1a,P G F 2a,
13,14-dihydro-15-keto PGE2,a n dT X B 2 were reduced at
the earliest time point only. An interesting pattern was
seen for LTB4, in which NSAID treatment caused an
initial increase at 8 hours but a significant reduction at
168 hours.
Additional material
Additional file 1: Calibration lines - Standard curve equations and
correlation coefficients for LC-ESI-MS/MS analysis of eicosanoid
standards. Calibration lines for liquid chromatography-electrospray
ionization-tandem mass spectrometry (LC-ESI-MS/MS) analysis were
prepared by diluting stock solutions to final concentrations of 100 pg/μL,
50 pg/μL, 25 pg/μL, 10 pg/μL, 5 pg/μL, 2 pg/μL and 1 pg/μL. The
internal standard (IS; 16,16-dimethyl prostaglandin F2a) was prepared in
ethanol (2 ng/μL) and added to all composite standards at a final
concentration of 100 pg/μL.
Abbreviations
BHT: butylated hydroxytoluene; ESI: electrospray ionization; HETE:
hydroxyeicosatetraenoic acid; HPLC: high-performance liquid
chromatography; IS: internal standard; LC: liquid chromatography; LDA: linear
discriminant analysis; LPS: lipopolysaccharide; LT: leukotriene; LX: lipoxin;
MMP: matrix metalloproteinase; MRM: multiple reaction monitoring; MS:
mass spectrometry; m/z: mass/charge; NSAID: non-steroidal anti-
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